T1	p 304 332	patients with chronic immune
T2	p 452 482	adults with previously treated
T3	p 799 817	computer-generated
T4	p 972 980	status .
T5	p 1494 1519	FINDINGS Between Nov 22 ,
T6	p 1536 1538	31
T7	p 1548 1565	197 patients were
T8	p 1605 1608	and
T9	p 1753 1762	treatment
T10	p 2075 2083	patients
T11	p 2209 2217	patients
T12	p 2345 2379	patients receiving eltrombopag had
T13	p 2479 2487	patients
T14	p 2731 2738	placebo
T15	p 2787 2788	(
T16	p 2965 2986	patients who have not
T17	p 3000 3023	splenectomy or previous
T18	i 6 17	Eltrombopag
T19	i 132 143	Eltrombopag
T20	i 155 186	thrombopoietin receptor agonist
T21	i 274 300	eltrombopag versus placebo
T22	i 424 442	placebo-controlled
T23	i 662 732	with local standard of care plus 50 mg eltrombopag or matching placebo
T24	i 1288 1289	4
T25	i 1358 1386	eltrombopag versus placebo .
T26	i 1678 1692	62 placebo ) .
T27	i 1838 1845	placebo
T28	i 1909 1920	eltrombopag
T29	i 1954 1961	placebo
T30	i 2094 2105	eltrombopag
T31	i 2175 2182	placebo
T32	i 2309 2316	placebo
T33	i 2436 2445	placebo .
T34	i 2511 2518	placebo
T35	i 2657 2666	placebo )
T36	i 2731 2738	placebo
T37	i 2818 2829	eltrombopag
T38	i 2847 2858	Eltrombopag
T39	o 51 69	thrombocytopenia (
T40	o 208 226	thrombocytopenia .
T41	o 333 349	thrombocytopenia
T42	o 490 509	thrombocytopenia of
T43	o 557 572	platelet counts
T44	o 872 886	platelet count
T45	o 937 971	thrombocytopenia , and splenectomy
T46	o 1115 1123	response
T47	o 1190 1204	platelet count
T48	o 1492 1493	.
T49	o 2247 2263	rescue treatment
T50	o 2380 2401	thromboembolic events
T51	o 2534 2543	increases
T52	o 2547 2591	alanine aminotransferase concentration , and
T53	o 2681 2701	in total bilirubin .
T54	o 2743 2766	serious bleeding events
T55	o 2905 2923	thrombocytopenia ,